IMI 10th Anniversary Scientific Symposium

Start Date 22/10/2018 End Date 23/10/2018
Brussels, Belgium

For the last 10 years, our projects – 100 and counting – have been carrying out amazing work to speed up the development of innovative medicines and transform medical research. At our 10th anniversary scientific symposium, held on 22-23 October 2018 in Brussels, young scientists from IMI projects showcased the stellar science that IMI projects have been doing.

The 72 posters and 28 oral presentations were selected by a Programme Committee comprising top experts, and were clustered around four themes. The best presenters of the presentations and posters (as judged by the Programme Committee and the audience) received prizes at the end of the event. Prizes were also awarded to the best IMI project communication products. These were selected by a committee of staff from IMI, the European Commission, and EFPIA.


Please find here the agenda

Poster session

Watch a short video of the poster session


Programme Committee prizes - best presentation

Programme Committee prizes - best poster

Audience choice

Best IMI project communication products


  1. “Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Mechanisms”​​​​​AETIONOMY - Holger Fröhlich, UCB
  2. “Quantitative PET Imaging - From Research to Clinical Use” AMYPAD - Fiona Heeman, VU University medical centre
  3. “Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: A showcase from the epidemiological studies within the IMI DIRECT Consortium” DIRECT - Robert Koivula, University of Oxford
  4. “Predicting Cognitive Decline through Structural MRI biomarkers: Results from the EMIF-AD Biomarker Discovery Study” EPAD - Silvia Ingala, VU Medical Center
  5. “The EU-AIMS Longitudinal European Autism Project: Examples of novel approaches to biomarker discovery” EU-AIMS - Stefan Holiga, F. Hoffmann-La Roche & Eva Loth, King's College London
  6. “Biomarker methods to enable stratification of patient populations in clinical trials for neuropathic pain” EUROPAIN - Jan Vollert, Imperial College London
  7. “Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors” Onco Track - Moritz Schütte, Alacris Theranostics GmbH
  8. “Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression” PRECISESADS - Daniel Toro, GENYO
  9. “Federating clinical data for biomedical research in type 2 diabetes” RHAPSODY - Thomas Sparsø, Novo Nordisk
  10. “Building handprints of complex diseases – severe asthma as a proof of concept” - U-BIOPRED and eTRIKS - Bertrand De Meulder, European Institute for Systems Biology and Medicine
  11. “Patient involvement in the IMI-APPROACH project: invaluable insights and key ingredients” APPROACH - Leonie Hussaarts, Lygature & Jane Taylor
  12. “Patient education is a prerequisite for meaningful patient engagement in the life cycle of medicines” EUPATI - Tamàs Bereczky, Eupati
  13. “Driving the use of Real World Evidence in healthcare decision making“ GETREAL - Amr Makady, Zorginstituut Nederland
  14. “When to consider patient preference information along the medical product lifecycle? An overview of decision points and situations” PREFER - Chiara Whichello and Eline van Overbeeke, KU Leuven
  15. “From development to labelling claim” - PRO-active - Heleen Demeyer, Uz Gasthuisberg
  16. “Baseline characteristics of participants of the SPRINTT randomised clinical trial” - SPRINTT - Riccardo Calvani, Università Cattolica del Sacro Cuore
  17. “An iPSC technology development collaboration – a critical component to enable ADAPTED” ADAPTED - Peter Reinhardt, AbbVie & Benjamin Schmid, Bioneer
  18. “Exploring the potential of lipidoid-polymer hybrid nanoparticles to deliver oligonucleotides to intracellular pharmacological targets” COMPACT - Thanki Kaushik, University of Copenhagen
  19. “Supporting stem cell research with modern data management technologies” EBISC - Stefanie Seltmann, Charité Berlin
  20. “EMIF Catalogue – the bridge between data custodians and biomedical researchers” - EMIF - Alina Trifan, University of Aveiro
  21. “HARMONY Platform: using Big Data to fight blood cancers” HARMONY - Maria Abáigar-Alvarado, Institute of Biomedical Research of Salamanca
  22. “Supersaturation as driving force for intestinal absorption resulting in an increased oral bioavaibility: case example with posaconazole” ORBITO - Bart Hens, KU Leuven
  23. “Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Study protocol“ RADAR-CNS - Faith Matcham, King's College London
  24. “EURECA - Substudy of infections due to carbapenem-resistant Enterobacteriacea (CRE) along Europe. Inside COMBACTE network; global information for a global problem” COMBACTE-CARE - Maria Paniagua, Hospital Universitario Virgen Macarena
  25. “A new European network for influenza vaccine effectiveness studies” DRIVE - Topi Turunen, FISABIO
  26. “Field validation of novel diagnostic tools for Ebola virus detection in Sierra Leone” - EbolaMoDRAD - Colavita Francesca, INMI
  27. “Modelling the humoral immune response to Ebola vaccine” - EBOVAC1 - Irene Balelli, Inserm
  28. “Highly potent heavy chain only antibodies protect against MERS-CoV infection” ZAPI - Nisreen Okba, Erasmus Medical Center


  1. “Support Translation Research with High Quality Data and Interactive Visual-analytics” eTRIKS - Kavita Rege, University of Luxembourg
  2. "Developing a robust evidence base on RSV disease and economic burden using a multi-disciplinary approach” - RESCEU - Rachel Reeves, University of Edinburgh
  3. “AMYPAD Diagnostic and Patient Management Study (AMYPAD-DPMS): rationale and study design"AMYPAD - Daniele Altomare, IRCCS Fatebenefratelli
  4. “Network-based modeling of APAP-induced hepatotoxicity using interactomics and transcriptomics data” - TransQST - Emre Guney, GRIB - IMIM / UPF
  5. “Stroke Risk, Bleeding Risk and Anticoagulation in Hospital EHRs” Big data @ heart - Daniel Bean, King's College London 
  6. “DPP6 as a new biomarker suitable for human islet in vivo imaging” - INNODIA - Stephane Demine, ULB Center for Diabetes Research
  7. “Identification of Stratified Social-Behavioural Markers in Neuropsychiatric Disorders by using smartphone technology” PRISM - Niels Jongs, Rijksuniversiteit Groningen
  8. “Drug Evaluation in Guinea Pig Model”PreDiCT TB -Faye Lanni, Public Health England
  9. “The APPROACH Consortium: a 2-year, European, cohort study to describe, validate, and predict phenotypes of knee osteoarthritis using clinical, imaging, and biochemical markers” APPROACH - Eefje Van Helvoort, University Medical Centre Utrecht
  10. “In vivo models of Drug-induced interstitial lung disease; tools to study and improve drug safety” TRISTAN - Irma Mahmutovic Persson, Lund University
  11. “RNA-sequencing of medulloblastoma patient-derived orthotopic xenograft models enables identification of both tumor and microenvironment specific biomarkers” - ITCC-P4 - Natalie Jäger, DKFZ and KiTZ, Heidelberg
  12. “Molecular characterization of patient-derived orthotopic xenograft models of paediatric brain tumours” ITCC-P4 - Sebastian Brabetz, Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ)
  13. “Candidate genes and pathways from ADAPTED Stage I integrative analysis” - ADAPTED - Laura Madrid Márquez, CAEBi Bioinformatica
  14. “Increased understanding of AD pathophysiology through novel cerebrospinal fluid markers: results from the EMIF-AD Multimodal Biomarker Discovery study” EMIF-AD - Isabelle Bos, Maastricht University
  15. “Data analytics and bioinformatics to successfully define asthma subphenotypes” U-BIOPRED - Stelios Pavlidis, Imperial College London
  16. “Collaborative capacity building: Creating new knowledge, new tools, new collaborative ties and educating young scientist” - K4DD - Tale Sliedrecht, Lygature
  17. “Developing a mechanism-based taxonomy of Alzheimer’s and Parkinson’s disease” AETIONOMY - Sepehr Golriz Khatami, Fraunhofer SCAI
  18. “Proteome analyses in colorectal carcinoma reveals major protein alterations upon cancer development and metastasis” OncoTrack - Alireza Azimi, Uppsala University
  19. “Human iPSC-derived cells: a powerful tool for neuropathic pain disease modelling” - NGN-PET - Lucia Rutigliano, Axxam
  20. “A new way to monitor Multiple Sclerosis” RADAR-CNS - Matteo Martinis, San Raffaele Hospital
  21. “Discovery of the role of the ELOVL2/docosahexaenoic acid axis in the regulation of insulin secretion and survival of rodent and human pancreatic beta cells” - IMIDIA - Lara Bellini, Paris Diderot University
  22. “Glucagon and gastrointestinal hormones changes after Roux-en-Y gastric bypass: an IMI DIRECT study” - DIRECT - Francesca Frau, Sanofi
  23. “Application and optimization of Monocyte Activation Test for testing Tick Borne Encephalitis virus vaccine pyrogenicity” VAC2VAC - Marilena Paola Etna, Instituto Superiore di Sanità
  24. “Development of Rift Valley fever virus neutralizing antibodies using bacterial superglues” ZAPI - Paul Wichgers Schreur, Wageningen Bioveterinary Research
  25. “Interim Pharmacokinetic Analysis from the EVADE Phase 2 Clinical Trial of MEDI3902, a Bispecific Monoclonal Antibody Against PcrV and Psl of Pseudomonas aeruginosa” COMBACTE-MAGNET - Ana Catalina Hernandez, Centre Hospitalier Universitaire de Limoges
  26. “Interim Pharmacokinetic Analysis from the SAATELLITE Phase 2 Clinical Trial of MEDI4893, an Extended Half-life Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin” COMBACTE-NET - Ana Catalina Hernandez, Centre Hospitalier Universitaire de Limoges
  27. “Urinary metabolites as potential biomarkers of P. aeruginosa ventilator-associated pneumonia” RAPP-ID - Bart Jongers, University of Antwerp
  28. “Laboratory Analysis workflows within the ASPIRE-ICU study” - COMBACTE-NET and COMBACTE-MAGNET - Leen Timbermont, University of Antwerp
  29. “New bio-informatic approach for the analysis of flow cytometry data” - PRECISESADS - Lucas Le Lann, University of Brest
  30. “Zebrafish Proteinopathy Models for Target Validation” - IMPRiND - Jeffrey Hubbard, Servier Research Institute
  31. “New candidate genes in insulin target tissues: Elovl2 as a protective enzyme against glycaemic deterioration?” - RHAPSODY - Justine Lallement, Paris Diderot University 
  32. “Integration of models of drug-induced liver injury for risk assessment” Trans-QST and MIP-DILI - Rowena Sison-Young, University of Liverpool
  33. “Isocyanide Chemistry (IMCR): Promising Technology For Future Drug Discovery And Development” ELF - Pravin Patil, University Of Groningen
  34. “Developing human cellular phenotypic assays for pain” StemBANCC - Satyan Chintawar, University of Oxford
  35. “Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells” - OncoTrack - Joseph Regan, Charité - Universitätsmedizin Berlin
  36. “A validated genetics-led system ‘Pi’ enables drug target discovery for immune traits” ULTRA-DD - Hai Fang, University Of Oxford
  37. “Immunobridging approach to assess clinical benefit as the basis for licensure of the monovalent Ebola vaccine” EBOVAC 1 and 2 - Viki Bockstal, Janssen Vaccines & Prevention
  38. “A Bordetella pertussis human challenge model induces immunising colonization in absence of symptoms” PERISCOPE - Hans de Graaf, University of Southampton
  39. “Translational Safety Assessment in Pharma” eTRANSAFE – Ruud Bueters, Janssen
  40. “In vitro antimicrobial activity of tobramycin, colistin, aztreonam and the new antibiotic POL7080 against cystic fibrosis Pseudomonas aeruginosa growing in biofilms” - iABC - María Díez-Aguilar, Hospital Universitario Ramón y Cajal-IRyCIS
  41. “Comparative assessment of seed extraction methods relevant for the study of Alzheimer disease” IMPRIND - Charlotte Delay, Janssen Pharmaceuticals
  42. “Frequencies of cerebrospinal fluid ATN biomarker profiles and their association with memory function in persons without dementia” EMIF-AD - Olin Jansen, Maastricht University
  43. “Developing predictive in silico models for liver toxicity endpoints from in vivo histopathology data” eTOX - Kevin Pinto Gil, University Pompeu Fabra
  44. “Prognostic factors and outcome of multiple myeloma patients enrolled in European clinical trials after a long-term follow-up. A pilot project by multiple myeloma community within HARMONY consortium” HARMONY - Mattia D'Agostino, University of Turin
  45. “Altering disease course before symptom onset: the European Prevention of Alzheimer’s Dementia (EPAD) project (WP4)” EPAD - Delia Gheorghe, University of Oxford
  46. “COMBACTE LAB-Net, a European laboratory network for clinical trials on anti-infectives to combat bacterial resistance” - COMBACTE-NET - Tomislav Kostyanev, University of Antwerp
  47. “Tools to collect data on detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories part of the COMBACTE Laboratory network (LAB-Net)“ COMBACTE-CARE and COMBACTE-NET - Tomislav Kostyanev, University of Antwerp
  48. “Exploring MMN processing in Autism Spectrum Disorder during the odd-ball task: evidence from the EU-AIMS LEAP cohort” - EU-AIMS - Jumana Ahmad, King's College London
  49. “Novel peptide vaccines against Rift valley fever virus” - ZAPI - Benjamin Gutjahr, Friedrich-Loeffler-Institut FLI
  50. “Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer’s Disease across the spectrum" ROADMAP - Amanda Ly, University of Edinburgh
  51. “Developmental changes in resting state power spectrum and functional connectivity in autism spectrum disorder” EU-AIMS - Pilar Garces, Roche
  52. “Implementing a Phase II Ebola Vaccine Trial (EBOVAC2) in Burkina Faso” - EBOVAC2 - Barry Houreratou, Centre MURAZ
  53. “A systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals” - EQIPD - Jan Vollert, Imperial College London
  54. “A Highly Productive Semi-Automated High Throughput Purification Process” ELF - Laura Mariana Levy, Taros
  55. “The Design and Synthesis of Innovative 3D Rich Scaffolds for Screening Libraries” ELF - Stanimira Hristeva, Taros
  56. “Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination: an observational cohort study" EBOVAC & EBOPLUS - Francesco Santoro, University of Siena
  57. “Transcriptomic analysis of the immune response to the rVSV-ZEBOV Ebola vaccine” VSV-EBOVAC - VSV-EBOPLUS - Francesco Santoro, University of Siena
  58. “What is responsible antibiotic use? Towards a global definition” DRIVE-AB - Annelie Monnier, Radboud University Medical Center & Hasselt University
  59. “The added value of quantitative amyloid PET in determining Alzheimer’s Disease (AD) dementia risk: the AMYPAD Prognostic and Natural History Study” AMYPAD - Isadora Lopes Alves, VU Medical Center Amsterdam
  60. “Towards an adaptive mindset” ADAPT SMART - Solange Rohou, Astrazeneca
  61. “Regulatory and HTA considerations for disease-modifying drugs in Alzheimer's disease” ROADMAP - Diana O'Rourke, National Institute for Health and Care Excellence (NICE)
  62. “Time-to-event case-control designs: An efficacious tool for cohort studies on nosocomial infections when resources are limited” COMBACTE - Jan Feifel, Ulm University
  63. “European Prevention of Alzheimer’s Dementia (EPAD) Registry for a longitudinal cohort and Alzheimer prevention trials” - EPAD - Lisa Vermunt, VU University Medical Center
  64. “Prioritisation and Intelligent Assessment of the Environmental Risks of Pharmaceuticals" iPiE - John Wilkinson, University of York
  65. “Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer’s Disease” - ROADMAP - Marieke Dekker, Medicines Evaluation Board (MEB-CBG)
  66. “IMI-PROTECT and benefit risk assessment” PROTECT - Edward Waddingham, Imperial College London
  67. “Managing false-positive Ebola test results in the post-outbreak era: Experiences in the EBOVAC vaccine trial in rural Sierra Leone” - EBOVAC - Frank Baiden, London School of Hygiene and Tropical Medicine
  68. “Characterising and appraising patient preference exploration and elicitation methods” PREFER - Chiara Whichello, Erasmus University Rotterdam
  69. “Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics” RESCEU - Joanne G. Wildenbeest, Wilhelmina Children's Hospital, University Medical Center Utrecht
  70. “Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes” PARADIGM - Chi Pakarinen, the Synergist
  71. “Lessons learned in the recruitment of adolescents and children to the EBOVAC-Salone clinical trial in Sierra Leone” EBOVAC1 - Shona Lee, EBOVAC Salone, Social Science Team
  72. "Bridging the gap between intention and action - Lessons learned from INNODIA’s Patient Advisory Committee” INNODIA - Jeannette Soderberg, JDRF

Meet the Programme Committee

The abstracts were reviewed by a Programme Committee made up of leading scientists from a range of fields. The committee was chaired by Professor Michel Goldman.

  • Professor Michel Goldman, Institute for Interdisciplinary Innovation in Healthcare (I³h), Université Libre de Bruxelles, Belgium
  • Professor Isabelle Bekeredjian-Ding, Paul Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany
  • Professor Daan Crommelin, Department of Pharmaceutics, Utrecht University, the Netherlands
  • Professor Maria Beatriz Da Silva Lima, Faculty of Pharmacy, Universidade de Lisboa, Portugal
  • Dr Diane Gosselin, Consortium Québécois sur la Découverte du Medicament (CQDM), Canada
  • Professor Trevor M Jones, Arix Bioscience plc, UK
  • Dr Ángeles Rodriguez Peña, Alberto Sols Biomedical Research Institute, Spain
  • Dr Cees Smit, The Netherlands Organisation for Health Research and Development, the Netherlands
  • Professor Tanel Tenson, Institute of Technology, University of Tartu, Estonia